466 Next generation sequencing of BRCA1 and BRCA2 genes in ovarian tumors captures all germline mutations and expands the potential treatment group for the PARP inhibitor olaparib
Kirsten M. Timms(Myriad (Germany)), Jerry S. Lanchbury(Myriad Genetics), L. Zhongwu, Anitra Fielding(AstraZeneca (United States)), Chris Neff(Myriad Genetics), Brian Dougherty(AstraZeneca (United States)), Darren Hodgson(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK), Stuart Spencer(AstraZeneca (United Kingdom)), Maria Orr(AstraZeneca (United Kingdom)), Alexander Gutin(Myriad Genetics), Carl Barrett(AstraZeneca (United Kingdom)), Brian Morris(University of Glasgow)
Cited by 0
Related Papers
A Draft Sequence of the Rice Genome ( <i>Oryza sativa</i> L. ssp. <i>japonica</i> )
|Science|2002|2.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k